Efficacy Of 100 Mg SC Mepolizumab For Severe Eosinophilic Asthma (SEA) Across Body Weight: Meta‐Analysis: 306
Abstract
Eric S. Bradford, MD, Camille Taill e, MD, PhD, Daniel J. Bratton, PhD, Steven W. Yancey, MSc, Namhee Kwon, MD, PhD, Frank Albers, MD, PhD, and Alberto Papi, MD; Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, Assistance PubliqueHôpitaux de Paris, Hôpital Bichat, Service de Pneumologie et Centre de R ef erence des Maladies Pulmonaires Rares, UMR1152, Paris, France, Clinical Statistics, GSK, Uxbridge, United Kingdom, Respiratory Medical Franchise, GSK, London, United Kingdom, Respiratory Medical Franchise, GSK, Research Triangle Park, NC, Research Center on Asthma and COPD, University of Ferrara, Ferrara, Italy. RATIONALE: Body weight can potentially influence the efficacy of severe asthma biologics treatment, requiring dose-weight adjustments. This analysis assessed the efficacy of the licensed, 100 mg subcutaneous (SC) dose ofmepolizumab in patients with SEA in different bodyweight & body mass index (BMI) categories. METHODS: Post hoc meta-analysis of the Phase 3 MENSA & MUSCA trials. Patients with SEA received mepolizumab 100 mg SC or placebo for 24 (MUSCA) & 32 (MENSA) weeks. Endpoint: annual rate of clinically significant exacerbations. Analyses were performed by baseline body weight categories (60–75, >75–90, >90 kg; _100 kg), & baseline BMI categories (20–25, >25–30, >30 kg/m; _36 kg/m). RESULTS: 936 patients were included (468 mepolizumab; 468 placebo; 227 [24%] on maintenance OCS). Across all weight categories, mepolizumab significantly reduced…
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.